2-amino-5-phosphonovalerate has been researched along with Alzheimer Disease in 7 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, reduces the clinical deterioration in moderate-to-severe Alzheimer disease (AD) for which other treatments are not available." | 3.72 | Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. ( Grundke-Iqbal, I; Haque, N; Iqbal, K; Li, L; Sengupta, A, 2004) |
| "The early phase of Alzheimer's disease (AD) is characterized by hippocampus-dependent memory deficits and impaired synaptic plasticity." | 1.42 | Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease. ( Barik, J; Bethus, I; Chafai, M; Kootar, S; Lanté, F; Marie, H; Mouska, X; Pereira, AR; Raymond, EF, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, L | 1 |
| Sengupta, A | 1 |
| Haque, N | 1 |
| Grundke-Iqbal, I | 1 |
| Iqbal, K | 1 |
| Ji, D | 1 |
| Lape, R | 1 |
| Dani, JA | 1 |
| Bi, X | 1 |
| Gall, CM | 1 |
| Zhou, J | 1 |
| Lynch, G | 1 |
| Porter, RH | 1 |
| Cowburn, RF | 1 |
| Alasuzoff, I | 1 |
| Briggs, RS | 1 |
| Roberts, PJ | 1 |
| Klunk, WE | 1 |
| McClure, RJ | 1 |
| Pettegrew, JW | 1 |
| Lanté, F | 1 |
| Chafai, M | 1 |
| Raymond, EF | 1 |
| Pereira, AR | 1 |
| Mouska, X | 1 |
| Kootar, S | 1 |
| Barik, J | 1 |
| Bethus, I | 1 |
| Marie, H | 1 |
| Birnbaum, JH | 1 |
| Bali, J | 1 |
| Rajendran, L | 1 |
| Nitsch, RM | 1 |
| Tackenberg, C | 1 |
7 other studies available for 2-amino-5-phosphonovalerate and Alzheimer Disease
| Article | Year |
|---|---|
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
Topics: 2-Amino-5-phosphonovalerate; Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase | 2004 |
Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Acetylcholine; alpha7 Nicotinic A | 2001 |
Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists.
Topics: 2-Amino-5-phosphonovalerate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cathepsin D; Culture | 2002 |
Heterogeneity of NMDA receptors labelled with [3H]3-((+-)-2-carboxypiperazin-4-yl) propyl-1-phosphonic acid ([3H]CPP): receptor status in Alzheimer's disease brains.
Topics: 2-Amino-5-phosphonovalerate; Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Animals; Bindi | 1992 |
L-phosphoserine, a metabolite elevated in Alzheimer's disease, interacts with specific L-glutamate receptor subtypes.
Topics: 2-Amino-5-phosphonovalerate; Alzheimer Disease; Animals; Dizocilpine Maleate; Dose-Response Relation | 1991 |
Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Dexamethasone; Disease Models, Animal; E | 2015 |
Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Dendritic Spines; Dizocilpine Maleate; E | 2015 |